4SC AG 2020 AR2
The report highlights 4SC's activities in 2020, a year heavily impacted by the COVID-19 pandemic. Despite challenges, the company advanced its clinical development programs for resminostat and domatinostat, including enrolling the first patients in the DONIMI and MERKLIN 2 studies. Financially, 4SC secured gross proceeds of approximately 7.5 million Euros through a cash capital increase in November 2020. The company ended the year with 48 employees and sufficient liquidity to fund operations into the second quarter of 2022.
Company: 4SC AG
Sector: Manufacturing
Country: Germany
Year: 2020
Type: AR2
Pages: 80
Back to company
4SC AG
Annual Report
The report highlights 4SC's activities in 2020, a year heavily impacted by the COVID-19 pandemic. Despite challenges, the company advanced its clinical development programs for resminostat and domatinostat, including enrolling the first patients in the DONIMI and MERKLIN 2 studies. Financially, 4SC secured gross proceeds of approximately 7.5 million Euros through a cash capital increase in November 2020. The company ended the year with 48 employees and sufficient liquidity to fund operations into the second quarter of 2022.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees